Payment overview · 2025
General Payments
$419.47
20 reported records · 7 companies
Healthcare provider profile · identity verified
Carlos Orces, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAREDO, TX · NPI 1164483400
Verified facts
What the public records show
CMS Open Payments records show Carlos Orces, MD received $419.47 in general payments during 2025 across 20 reported records.
Janssen Biotech, Inc. accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enbrel, Otezla, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Otezla by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $196.92 | 46.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.96 | 14.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $48.26 | 11.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.09 | 10.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.69 | 7.8% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $21.19 | 5.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.36 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $419.47 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $196.92 | 8 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $48.26 | 3 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $44.09 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENBREL enbrel |
2025 | Enbrel | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 431 | 88 |
| Omeprazole | Omeprazole | 346 | 98 |
| Alprazolam | Alprazolam | 316 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 97 |
| Losartan Potassium | Losartan Potassium | 305 | 90 |
| Celecoxib | Celecoxib | 261 | 85 |
| Lorazepam | Lorazepam | 256 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 230 | 56 |
| Meloxicam | Meloxicam | 229 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 56 |
| Gabapentin | Gabapentin | 218 | 60 |
| Metformin Hcl | Metformin Hcl | 202 | 63 |
| Enbrel Sureclick | Etanercept | 178 | 22 |
| Lisinopril | Lisinopril | 170 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 158 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 68 |
| Glimepiride | Glimepiride | 148 | 37 |
| Methylprednisolone | Methylprednisolone | 144 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 43 |
| Ozempic | Semaglutide | 141 | 27 |
| Prednisone | Prednisone | 132 | 42 |
| Jardiance | Empagliflozin | 129 | 27 |
| Methotrexate | Methotrexate Sodium | 124 | 23 |
| Leflunomide | Leflunomide | 123 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 29 |
| Buspirone Hcl | Buspirone Hcl | 110 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 20 |
| Alendronate Sodium | Alendronate Sodium | 103 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 21 |
| Furosemide | Furosemide | 99 | 29 |
| Azithromycin | Azithromycin | 93 | 66 |
| Ibuprofen | Ibuprofen | 73 | 22 |
| Pregabalin | Pregabalin | 73 | 12 |
| Farxiga | Dapagliflozin Propanediol | 70 | 24 |
| Montelukast Sodium | Montelukast Sodium | 69 | 22 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 69 | 28 |
| Enbrel | Etanercept | 67 | suppressed |
| Levofloxacin | Levofloxacin | 67 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 60 | suppressed |
| Clonazepam | Clonazepam | 59 | 11 |
| Potassium Chloride | Potassium Chloride | 57 | 13 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 42 |
| Cilostazol | Cilostazol | 50 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 16 |
| Olanzapine | Olanzapine | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 11 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | 13 |
| Cimzia (2 Pack) | Certolizumab Pegol | 45 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | 26 |
| Simvastatin | Simvastatin | 44 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 23 |
| Sertraline Hcl | Sertraline Hcl | 41 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Folic Acid | Folic Acid | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Rinvoq | Upadacitinib | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Humira(Cf) Pen | Adalimumab | 26 | suppressed |
| Enulose | Lactulose | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 12 |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Felodipine Er | Felodipine | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Azathioprine | Azathioprine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Humira Pen | Adalimumab | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Otezla | Apremilast | 14 | suppressed |
| Xeljanz | Tofacitinib Citrate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | 13 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $419.47 · 20 records | Janssen Biotech, Inc. | BENLYSTA, ENBREL, EVENITY, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, PROLIA, PURIFIED CORTROPHIN GEL, RINVOQ, TREMFYA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enbrel play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error